Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

Sudeepa Bhattacharyya, Ahmed T. Ahmed, Matthias Arnold, Duan Liu, Chunqiao Luo, Hongjie Zhu, Siamak Mahmoudiandehkordi, Drew Neavin, Gregory Louie, Boadie W. Dunlop, Mark A. Frye, Liewei Wang, Richard M. Weinshilboum, Ranga R. Krishnan, A. John Rush, Rima Kaddurah-Daouk

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD17) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that are known to be influenced by human gut microbial cometabolism. 5HT, 5-hydroxyindoleacetate (5HIAA), and the ratio of 5HIAA/5HT showed significant correlations to temporal changes in HRSD17 scores. In the tyrosine pathway, changes were observed in the end products of the catecholamines, 3-methoxy-4-hydroxyphenylethyleneglycol and vinylmandelic acid. Furthermore, two phenolic acids, 4-hydroxyphenylacetic acid and 4-hydroxybenzoic acid, produced through noncanconical pathways, were increased with drug exposure. In the purine pathway, significant reductions in hypoxanthine and xanthine levels were observed. Examination of metabolite interactions through differential partial correlation networks revealed changes in guanosine–homogentisic acid and methionine–tyrosine interactions associated with HRSD17. Genetic association studies using the ratios of these interacting pairs of metabolites highlighted two genetic loci harboring genes previously linked to depression, neurotransmission, or neurodegeneration. Overall, exposure to escitalopram/citalopram results in shifts in metabolism through noncanonical pathways, which suggest possible roles for the gut microbiome, oxidative stress, and inflammation-related mechanisms.

Original languageEnglish (US)
Article number173
JournalTranslational psychiatry
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients'. Together they form a unique fingerprint.

  • Cite this

    Bhattacharyya, S., Ahmed, A. T., Arnold, M., Liu, D., Luo, C., Zhu, H., Mahmoudiandehkordi, S., Neavin, D., Louie, G., Dunlop, B. W., Frye, M. A., Wang, L., Weinshilboum, R. M., Krishnan, R. R., Rush, A. J., & Kaddurah-Daouk, R. (2019). Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational psychiatry, 9(1), [173]. https://doi.org/10.1038/s41398-019-0507-5